

<b>Policy Name:</b>	<b>Adzyna (ADAMTS13 Recombinant)</b>	<b>Policy#:</b>	<b>3232P</b>
---------------------	--------------------------------------	-----------------	--------------

## Purpose of the Policy

The purpose of this policy is to define coverage criteria for Adzyna (ADAMTS13 Recombinant)

## Statement of the Policy

Health Alliance Medical Plans and Health Alliance Northwest will approve the use of Adzyna (ADAMTS13 Recombinant) under the specialty medical benefit if the following criteria are met.

## Criteria

### 1. Coverage Criteria

- 1.1 Diagnosis of severe congenital (hereditary) thrombotic thrombocytopenic purpura (cTTP) confirmed by both of the following:
  - Genetic testing showing mutation in the ADAMTS13 gene
  - ADAMTS13 enzyme activity testing showing <10% of normal ADAMTS13 activity in the absence of ADAMTS13 antibodies
- 1.2 Prescribed by or in consultation with a hematologist (blood doctor), oncologist (cancer doctor) or other specialist in blood disorders
- 1.3 For on-demand therapy: documentation that patient is experiencing a 50% or greater drop in platelet count or platelet count is <100,000/microliter
- 1.4 For prophylactic therapy: patient must have a history of at least one documented TTP event while receiving prophylactic plasma based therapy
- 1.5 Requests for coverage must be reviewed by both a pharmacist and medical director

### 2. Exclusion Criteria

- 2.1 Diagnosis of acquired or immune mediated thrombotic thrombocytopenic purpura (iTTP) or any other thrombocytopenic disorder

### 3. Approval Period

- 3.1 Initial: 12 months
- 3.2 Reauth: 12 months with documentation of positive clinical response such as improvement in acute and subacute TTP events, platelet counts, microangiopathic hemolytic anemia episodes, or clinical symptoms

## CPT Codes

--	--

## HCPCS Codes

--	--

## References

1. Adzyna (ADAMTS13 Recombinant) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; November 2023.
2. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. *J Thromb Haemost.* 2020;18(10):2496-2502.
3. Scully M, Rayment R, Clark A, et al; BSH Committee. A British Society for Haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. *Br J Haematol.* 2023;203(4):546-563

**Created Date: 02/07/24**

**Effective Date: 02/07/24**

**Posted to Website: 02/07/24**

**Revision Date:**

### DISCLAIMER

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.